FDA waves Epizyme’s $186K rare cancer drug through to market — now get ready for the second act

0
103
FDA waves Epizyme’s $186K rare cancer drug through to market — now get ready for the second act

Af­ter win­ning the hearts of the ex­pert pan­el con­vened by the FDA de­spite a bleak in-house re­view and a check­ered de­vel­op­ment his­to­ry, Robert Baze­more has steered Epizyme to its first-ever OK for a rare can­cer drug.
The ap­proval in ep­ithe­lio…
%%

LEAVE A REPLY

Please enter your comment!
Please enter your name here